Hermetica Superfood Encyclopedia
The Short Answer
Akuamma seeds contain indole alkaloids — principally akuammine, akuammicine, and akuammidine — that interact with opioid and adrenergic receptors to produce analgesic and antihypertensive effects while flavonoids and saponins (3.46% and 3.45% respectively) confer antioxidant and antimicrobial activity. Preclinical evidence in rodent models shows that aqueous seed extract at 200–400 mg/kg significantly elevated plasma and hepatic glutathione and superoxide dismutase levels (P < 0.05) and modulated lipid-metabolism genes HMG-CoA reductase and CPT-1α, but no human clinical trials have established effective or safe supplemental doses.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary Keywordakuamma benefits
Akuamma — botanical close-up
Health Benefits
**Analgesic and Pain Relief**
Akuammine and akuammicine bind opioid receptors (particularly mu- and delta-subtypes) producing dose-dependent antinociception in animal models, forming the pharmacological basis for the seed's traditional role as a pain remedy in Akan and broader West African medicine.
**Antimalarial Activity**
Alkaloid fractions from Picralima nitida seeds have demonstrated activity against Plasmodium falciparum in vitro, consistent with the plant's long-standing ethnomedicinal use as a fever and malaria treatment across Ghana and Nigeria.
**Antioxidant Defense**
At 200–400 mg/kg in high-fat/high-fructose-fed rats, aqueous seed extract significantly increased glutathione (GSH) and superoxide dismutase (SOD) activity (P < 0.05), suggesting the flavonoids and phenolics neutralize reactive oxygen and nitrogen species and reduce oxidative stress.
**Lipid Metabolism Modulation**
Seed extract downregulated HMG-CoA reductase expression at all tested doses and upregulated CPT-1α (carnitine palmitoyltransferase-1α) at 400 mg/kg in dyslipidemic rats, indicating potential to reduce hepatic cholesterol synthesis while promoting mitochondrial fatty acid oxidation.
**Antihypertensive Effects**
Cholinomimetic (muscarinic) substances identified in aqueous seed extracts produce hypotensive effects by facilitating vascular smooth muscle relaxation, corroborating traditional use of the plant for managing high blood pressure.
**Antimicrobial Properties**
Phenolics, flavonoids, and saponins from seed and peel extracts disrupt bacterial phospholipid bilayers, demonstrating broad-spectrum antimicrobial activity against pathogens including Staphylococcus aureus and Escherichia coli in laboratory assays.
**Antidiabetic Potential**
Preclinical models suggest Picralima nitida extracts may improve glycemic parameters, likely through inhibition of carbohydrate-digesting enzymes and enhancement of insulin-sensitizing pathways, though specific molecular targets and human data remain unestablished.
Origin & History
Natural habitat
Picralima nitida is a tropical tree native to the rainforest belt of West and Central Africa, with documented presence in Ghana, Nigeria, Ivory Coast, Cameroon, and the Democratic Republic of Congo. It thrives in humid, lowland tropical forest environments with high rainfall and rich alluvial soils. The plant is not widely cultivated commercially and is primarily harvested from wild populations, with seeds, bark, and roots used by local communities.
“Picralima nitida has been used for centuries in the traditional medicine of the Akan people of Ghana and related ethnic groups across West and Central Africa, where the seeds — called 'akuamma' — are among the most recognized herbal analgesics and antipyretics. The seeds are commonly prescribed by traditional healers for malaria, dysentery, diarrhea, hypertension, pain, and general inflammation, and the plant occupies a significant place in the materia medica of Ghana, Nigeria, Cameroon, and Ivory Coast. Preparation typically involves drying and powdering the seeds for direct oral ingestion or preparing aqueous decoctions of seeds and peels, with the bitter taste considered indicative of potency by traditional practitioners. The plant's entry into Western ethnopharmacological literature occurred in the mid-20th century following colonial-era botanical surveys, and systematic alkaloid isolation began in the 1960s–1980s, establishing the scientific basis for many of its traditional uses.”Traditional Medicine
Scientific Research
The scientific evidence base for Akuamma consists entirely of in vitro and animal studies; no peer-reviewed human clinical trials with defined sample sizes or effect sizes have been published as of the available literature. Rodent studies using high-fat/high-fructose diet models demonstrated statistically significant antioxidant gene modulation (P < 0.05) and lipid-metabolism gene expression changes at 200–400 mg/kg aqueous seed extract, but exact group sizes were not reported in accessible publications. Acute toxicity studies in mice yielded an LD50 of approximately 8852–9120 mg/kg depending on calculation method (Karber-Behrens vs. graphical), classifying the extract as slightly toxic under standard OECD thresholds, though these findings cannot be directly extrapolated to chronic human exposure. Antimalarial, antimicrobial, antidiabetic, and anti-inflammatory effects have been documented in laboratory assays, but rigorous dose-finding, pharmacokinetic, and safety studies in humans are absent, placing confidence in therapeutic claims at a preliminary level.
Preparation & Dosage
Traditional preparation
**Traditional Powdered Seeds**
1–3 g of seed powder per dose)
Dried seeds are ground into a coarse powder and taken orally, often mixed with water or soft food; no validated human dose exists, though traditional use involves small quantities (estimated .
**Aqueous Decoction**
Seeds or peels are boiled in water to produce a tea or decoction used for fever, malaria, and pain; concentration is highly variable and unstandardized.
**Aqueous Seed Extract (Preclinical Reference Dose)**
200–400 mg/kg in rodents demonstrated antioxidant and lipid-modulating effects; human equivalent dose calculations (using standard body surface area conversion factor of ~6
2) would suggest approximately 32–65 mg/kg in humans, but this extrapolation is speculative and not clinically validated.
**Standardized Alkaloid Extract**
500 mg ground seed powder, but alkaloid content and purity are unverified by independent testing
Not commercially standardized; some suppliers market capsules at .
**Methanol/Chloroform Extracts**
Used exclusively in laboratory research for phytochemical isolation; not appropriate for human consumption.
**Timing Notes**
No pharmacokinetic data exist to inform optimal timing, meal interactions, or dosing frequency in humans.
Nutritional Profile
Picralima nitida peels offer notable macronutrient content, with approximately 265.8 kcal per 100 g dry weight, 28.4% crude protein, 37.7% carbohydrates, and 7.4% lipids, suggesting meaningful caloric and protein value as a food or feed ingredient. Phytochemical concentrations in seed and peel extracts include flavonoids (~3.46%), saponins (~3.45%), tannins (~2.02%), and total alkaloids (~2.03%), alongside terpenes, sterols, phenolics, and glycosides at lower concentrations. Micronutrient analysis reveals the presence of essential minerals including zinc, iron, and manganese, as well as fat-soluble vitamins A and E and a complement of amino acids consistent with its protein content. Bioavailability of alkaloids and polyphenols is likely modulated by the concurrent presence of tannins (which can bind alkaloids and reduce absorption) and saponins (which may enhance intestinal permeability), but no quantitative human bioavailability studies have been conducted.
How It Works
Mechanism of Action
The primary alkaloids akuammine, akuammicine, and akuammidine — which together constitute approximately 2.03% of seed dry weight — interact with mu- and delta-opioid receptors to produce analgesia and with adrenergic pathways to modulate vascular tone, accounting for both pain-relieving and hypotensive effects. Flavonoids and phenolics scavenge superoxide anions and reactive nitrogen species directly while also upregulating endogenous antioxidant enzymes; in rat models, seed extract at 200–400 mg/kg significantly elevated hepatic and plasma GSH and SOD (P < 0.05 vs. controls), indicating transcriptional or post-translational activation of the Nrf2 antioxidant response pathway. At the lipid-metabolism level, the extract suppresses hepatic HMG-CoA reductase gene expression across all doses tested, reducing the rate-limiting step of cholesterol biosynthesis, while the 400 mg/kg dose additionally upregulates CPT-1α, enhancing mitochondrial import and β-oxidation of long-chain fatty acids. Saponins and phenolics exert antimicrobial effects by intercalating into and destabilizing bacterial phospholipid bilayers, increasing membrane permeability and causing leakage of intracellular contents.
Clinical Evidence
No human randomized controlled trials or observational clinical studies have been conducted on Akuamma supplementation, meaning all clinical inferences are extrapolated from animal and cell-based data. The most quantified preclinical outcomes involve antioxidant enzyme modulation (GSH and SOD elevation, P < 0.05) and lipid-gene expression changes in dyslipidemic rats administered 200–400 mg/kg aqueous seed extract. Acute toxicity profiling in mice established an LD50 above 8800 mg/kg, suggesting a wide margin between pharmacologically active and acutely lethal doses in rodents, but chronic toxicity, human pharmacokinetics, and dose-translation coefficients remain entirely uncharacterized. The overall confidence in clinical benefit claims is low; Akuamma should be considered a bioactive-rich ethnomedicinal plant warranting rigorous Phase I and Phase II investigation rather than a clinically validated supplement.
Safety & Interactions
Acute toxicity studies in mice classify Picralima nitida aqueous seed extract as slightly toxic, with an LD50 of approximately 8852–9120 mg/kg, which is well above the 5000 mg/kg threshold used to define low acute toxicity under OECD guidelines; however, chronic toxicity, genotoxicity, and reproductive toxicity data in either animals or humans are absent. The cholinomimetic (muscarinic) activity of aqueous extracts poses a clinically meaningful risk of hypotension, and concurrent use with antihypertensive medications, cholinergic drugs, or cholinesterase inhibitors should be avoided until interaction studies are available. No cardiac glycosides or hydrogen cyanides have been detected in analyzed samples, which reduces some toxicological concern, but the opioid receptor activity of akuammine and akuammicine theoretically warrants caution in patients taking opioid analgesics or those with respiratory depression risk. Pregnant and lactating individuals should avoid Akuamma due to complete absence of safety data in these populations, and no maximum safe human dose has been established.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Picralima nitidaAkuamma seedPicralima klaineanaFuntumia nitidaEbur seeds
Frequently Asked Questions
What is akuamma used for traditionally?
In West and Central African ethnomedicine, akuamma seeds have been used primarily as an analgesic, antimalarial, and antipyretic remedy by the Akan people of Ghana and neighboring communities. Traditional healers prescribe powdered seeds or aqueous decoctions for malaria, dysentery, hypertension, pain, and inflammation, relying on the seed's bitter alkaloid content — particularly akuammine and akuammicine — as indicators of therapeutic potency.
How does akuamma relieve pain?
The analgesic effect of akuamma is attributed primarily to its indole alkaloids, akuammine and akuammicine, which have been shown to interact with mu- and delta-opioid receptors in a manner structurally analogous to opioid compounds, producing antinociceptive effects in animal models. Unlike classical opioids, akuammine's partial or biased receptor activity may confer analgesia with a potentially different side-effect profile, though no human studies have confirmed this distinction or established a safe effective dose.
Is akuamma safe to take as a supplement?
Acute toxicity studies in mice show an LD50 above 8800 mg/kg for aqueous seed extract, suggesting low acute toxicity, but chronic toxicity, drug interaction, and human pharmacokinetic data are entirely absent. The cholinomimetic compounds in the extract can cause blood pressure drops, making it potentially hazardous for people on antihypertensive or cholinergic medications, and no standardized safe human dose has been established by regulatory or clinical bodies.
What are the active compounds in akuamma seeds?
Akuamma seeds contain a complex mixture of bioactive constituents, with indole alkaloids — primarily akuammine, akuammicine, and akuammidine at approximately 2.03% total alkaloid content — representing the most pharmacologically studied compounds. Additional phytochemicals include flavonoids (3.46%), saponins (3.45%), tannins (2.02%), phenolics, terpenes, sterols, and glycosides, along with micronutrients such as zinc, iron, manganese, and vitamins A and E.
What is the recommended dosage of akuamma?
No validated human supplemental dose has been established for akuamma; all dose data come from preclinical rodent studies where 200–400 mg/kg aqueous seed extract produced statistically significant antioxidant and lipid-modulating effects. Commercial capsule products typically contain 500 mg of ground seed powder per serving, but alkaloid content is unstandardized and independent quality verification is rarely available, making dosing guidance speculative at this stage of research.
Does akuamma interact with opioid medications or pain relievers?
Yes, akuamma may interact with opioid medications since its active alkaloids (akuammine and akuammicine) bind to the same opioid receptors that prescription opioids target, potentially increasing side effects or creating unpredictable interactions. Combining akuamma with other pain medications, particularly opioids or nonsteroidal anti-inflammatory drugs (NSAIDs), should only be done under medical supervision. It is important to disclose akuamma use to your healthcare provider before taking any pain medications.
Is akuamma safe to use during pregnancy or while breastfeeding?
There is insufficient clinical research on akuamma's safety during pregnancy and breastfeeding, and it should be avoided during these periods as a precautionary measure. The alkaloid content and potential effects on opioid receptors raise concerns about fetal development and infant exposure through breast milk. Pregnant or nursing women should consult their healthcare provider before considering any akuamma supplementation.
What does current clinical research show about akuamma's effectiveness compared to conventional pain medications?
Most evidence for akuamma comes from traditional use and animal studies demonstrating opioid receptor binding and dose-dependent pain relief, but robust human clinical trials comparing it directly to conventional analgesics are limited. Available research suggests the alkaloid fraction has antimalarial and analgesic potential, yet the quality and scale of human studies lag behind approval-stage research for pharmaceutical pain medications. More rigorous clinical trials are needed to establish akuamma's efficacy and safety profile relative to standard treatments.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w akuamma-picralima-nitida curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
